Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
- 30 May 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (27) , 18241-18252
Abstract
Aberrant DNA repair is a hallmark of cancer, and many tumors display reduced DNA repair capacities that sensitize them to genotoxins. Here, we demonstrate that the differential DNA repair capacities of healthy and transformed tissue may be exploited to obtain highly selective chemotherapies. We show that the novel N3-(2-fluoroethyl)imidazotetrazine "KL-50" is a selective toxin toward tumors that lack the DNA repair protein O6-methylguanine-DNA-methyltransferase (MGMT), which reverses the formation of O6-alkylguanine lesions. We establish that KL-50 generates DNA interstrand cross-links (ICLs) by a multistep process comprising DNA alkylation to generate an O6-(2-fluoroethyl)guanine (O6FEtG) lesion, slow unimolecular displacement of fluoride to form an N1,O6-ethanoguanine (N1,O6EtG) intermediate, and ring-opening by the adjacent cytidine. The slow rate of N1,O6EtG formation allows healthy cells expressing MGMT to reverse the initial O6FEtG lesion before it evolves to N1,O6EtG, thereby suppressing the formation of toxic DNA-MGMT cross-links and reducing the amount of DNA ICLs generated in healthy cells. In contrast, O6-(2-chloroethyl)guanine lesions produced by agents such as lomustine and the N3-(2-chloroethyl)imidazotetrazine mitozolomide rapidly evolve to N1,O6EtG, resulting in the formation of DNA-MGMT cross-links and DNA ICLs in healthy tissue. These studies suggest that careful consideration of the rates of chemical DNA modification and biochemical DNA repair may lead to the identification of other tumor-specific genotoxic agents.Keywords
All Related Versions
Funding Information
- National Cancer Institute (1R01CA276186, U19CA264362)
- Yale Cancer Center
- U.S. Department of War (W81XWH2110547)
- National Institute of General Medical Sciences (R35-GM131913)
- Modifi Biosciences
This publication has 76 references indexed in Scilit:
- Glioblastoma and Other Primary Brain Malignancies in AdultsJAMA, 2023
- Cancer models in preclinical research: A chronicle review of advancement in effective cancer researchAnimal Models and Experimental Medicine, 2021
- DNA Damaging Drugs2015
- Detection and Characterization of 1,2‐Dibromoethane‐Derived DNA Crosslinks Formed with O6‐Alkylguanine‐DNA AlkyltransferaseAngewandte Chemie International Edition, 2013
- Synthesis of DNA Interstrand Cross‐Links Using a Photocaged NucleobaseAngewandte Chemie International Edition, 2012
- Assessment of DNA Interstrand Crosslinks Using the Modified Alkaline Comet Assay2011
- Phase I study of mitozolomide on a once daily for 5 days scheduleCancer Chemotherapy and Pharmacology, 1990
- Phase II study of mitozolomide (M & B 39,565) in head and neck cancerMedical Oncology and Tumor Pharmacotherapy, 1989
- Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancerInvestigational New Drugs, 1988
- 5‐[3‐(2‐chloroethyl)‐1‐triazenyl]imidazole‐4‐carboxamide and a Possible Mechanism of Action of 5‐[3,3‐Bis(2‐chloroethyl)‐1‐triazenyl]imidazole‐4‐carboxamideJournal of Pharmaceutical Sciences, 1975